Business
NuGen Medical Devices Announces NHS Drug Tariff Approval for EziAutoJector(R) Product Line in the UK
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD)...
About this update from Nugen Medical Devices Inc
[{"type":"text","content":"NuGen Medical Devices Announces NHS Drug Tariff Approval for EziAutoJector(R) Product Line in the UKToronto, Ontario--(Newsfile Corp. - September 26, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) (\"NuGen\" or the \"Company\"), a leader in needle-free subcutaneous drug-delivery technology, is pleased to announce that its exclusive UK distribution partner, EziAutoJector® Ltd, has received confirmation from the NHS Business Services Authority, on behalf of the Department of Health, that EziAutoJector® products have been approved for inclusion in the NHS Drug Tariff.This milestone provides for individuals with diabetes who are prescribed EziAutoJector® by their healthcare provider to receive the EziAutoJector® needle-free insulin delivery device and its accessories at no cost, as part of their NHS-funded diabetes care. Aligning with the National Institute for Health and Care Excellence (NICE) guidelines, which advocate for personalised patient choice in insulin delivery methods, this should then ensure pharmacists are reimbursed for dispensing the product. EziAutoJector® Ltd has established supply channels through a major pharmaceutical wholesaler, enabling distribution to both high-street pharmacies and direct-to-patient via online pharmacy services. EziAutoJector® Ltd's UK market strategy includes targeted educational initiatives designed to engage diabetes healthcare professionals, pharmacists, patients, and caregivers-aimed at increasing awareness, understanding, and advocacy for the EziAutoJector® product range.Additionally, a direct-to-consumer (D2C) e-commerce channel will support patients in regions where prescribing restrictions currently limit access, ensuring broader availability of the technology.By transitioning to EziAutoJector®, each patient eliminates the use of over 1,000 single-use insulin needles annually-significantly reducing biohazardous waste and the environmental footprint associated with its collection and disposal. This contributes to a more sustainable approach to diabetes management and supports the NHS in achieving its environmental and cost-efficiency goals.\"NHS reimbursement approval marks a significant step forward for EziAutoJector® Ltd and for NuGen Medical Devices,\" said Liang Lin, CEO of NuGen Medical Devices. \"It enables people living with diabet...